Successful Rechallenge of Hepaftocellular Carcinoma with Atezolizumab and Bevacizumab Following Disease Progression
Systemic therapies to treat Hepatocellular Carcinoma (HCC), a cancer with traditionally poor prognosis, have greatly advanced in the last five years with the advent of immunotherapies. The immune checkpoint inhibitor atezolizumab and anti-angiogen ic agent bevacizumab combination therapy is now recommend ed as first line treatment for unresectable HCC. Bevacizumab is associated with an increased risk of severe variceal or mucosal bleeding. We present a remarkable case of a patient with multifo cal HCC being treated with combination atezolizumab and bev acizumab therapy. The patient experienced complete response to combination therapy.
